Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert I Nicholson

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Clinical & Experimental Metastasis|September 25, 2004
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839)Stephen Hiscox, Liam Morgan, Denise Barrow, et al.
Clinical & Experimental Metastasis|March 31, 2007
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cellsStephen Hiscox, Nicola J Jordan, Liam Morgan, et al.
Journal of Drug Targeting|December 8, 2005
HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell linesFrancesca Greco, María J Vicent, Neal A Penning, et al.
Journal of Cellular Biochemistry|March 31, 2009
Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cellsShefali Soni, Bor-Tyh Lin, Avery August, et al.
Breast Cancer Research and Treatment|December 8, 2005
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cellsStephen Hiscox, Liam Morgan, Tim P Green, et al.
Pharmaceutical Research|July 16, 2008
In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skinZoë Davison, Carol Dutkowski, Julia M W Gee, et al.
The Biochemical Journal|July 4, 2003
Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transportersKathryn M Taylor, Helen E Morgan, Andrea Johnson, et al.
Endocrinology|June 28, 2008
ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer CellsKathryn M Taylor, Petra Vichova, Nicola Jordan, et al.
Anticancer Research|August 15, 2002
Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifenNigel J Bundred, Elizabeth Anderson, Robert I Nicholson, et al.
Breast Cancer Research and Treatment|September 21, 2004
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cellsNicola J Jordan, Julia M W Gee, Denise Barrow, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Clinical & Experimental Metastasis|September 25, 2004
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839)Stephen Hiscox, Liam Morgan, Denise Barrow, et al.
Clinical & Experimental Metastasis|March 31, 2007
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cellsStephen Hiscox, Nicola J Jordan, Liam Morgan, et al.
Journal of Drug Targeting|December 8, 2005
HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell linesFrancesca Greco, María J Vicent, Neal A Penning, et al.
Journal of Cellular Biochemistry|March 31, 2009
Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cellsShefali Soni, Bor-Tyh Lin, Avery August, et al.
Breast Cancer Research and Treatment|December 8, 2005
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cellsStephen Hiscox, Liam Morgan, Tim P Green, et al.
Pharmaceutical Research|July 16, 2008
In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skinZoë Davison, Carol Dutkowski, Julia M W Gee, et al.
The Biochemical Journal|July 4, 2003
Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transportersKathryn M Taylor, Helen E Morgan, Andrea Johnson, et al.
Endocrinology|June 28, 2008
ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer CellsKathryn M Taylor, Petra Vichova, Nicola Jordan, et al.
Anticancer Research|August 15, 2002
Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifenNigel J Bundred, Elizabeth Anderson, Robert I Nicholson, et al.
Breast Cancer Research and Treatment|September 21, 2004
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cellsNicola J Jordan, Julia M W Gee, Denise Barrow, et al.
Pageof 8